Navigation Links
SYMLIN Pen-Injector Devices Now Available
Date:1/7/2008

SymlinPen Offers Convenient SYMLIN Administration for Enhanced Glucose

Control With Potential Weight Loss

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today the availability of the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R) (pramlintide acetate) injection. These new pre-filled pen-injector devices feature simple, fixed dosing to improve mealtime glucose control.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080107/LAM117)

"SYMLIN offers enhanced blood glucose control with potential weight loss for patients with diabetes using mealtime insulin, enabling them to do more to manage their diabetes," said Daniel M. Bradbury, President and CEO, Amylin Pharmaceuticals. "The convenience of the new SymlinPen(TM) with simple, fixed dosing will make it easier for these patients using multiple daily injections to start and stay with SYMLIN."

SymlinPen(TM) 120 features fixed dosing to deliver 60 or 120 micrograms of SYMLIN per dose. SymlinPen(TM) 60 features fixed dosing to deliver 15, 30, 45, or 60 micrograms of SYMLIN per dose. Both pen-injector devices can be conveniently stored at room temperature not to exceed 86 degrees F (30 degrees C) after first use.

About SYMLIN

SYMLIN is an injectable medicine used to control blood sugar after meals in adults with type 2 or type 1 diabetes who take mealtime insulin. SYMLIN is the first and only amylin mimetic for use in patients with diabetes treated with mealtime insulin. SYMLIN is a synthetic analog of human amylin, a naturally occurring hormone that is made in the beta cells of the pancreas, the same cells that make insulin. In patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes, those cells in the pancreas are either damaged or destroyed, resulting in reduced secretion of both insulin and amylin after meals. The use of SYMLIN contributes to glucose control after meals.

Healthcare professionals and people with diabetes may obtain more information, including the complete Prescribing Information and the Medication Guide, at http://www.SYMLIN.com.

Important Safety Information

SYMLIN is not intended for all patients with diabetes. SYMLIN is used with insulin and has been associated with an increased risk of insulin-induced severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia associated with SYMLIN use occurs, it is seen within three hours following a SYMLIN injection. If severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities, serious injuries may occur. Appropriate patient selection, careful patient instruction, and insulin dose adjustments are critical elements for reducing this risk. This information is highlighted in a boxed warning in the SYMLIN Prescribing Information for healthcare

professionals and in a Medication Guide for patients, which will be distributed by pharmacists.

Other adverse events commonly observed with SYMLIN when co-administered with insulin were mostly gastrointestinal in nature, including nausea, which was the most frequently reported. The incidence of nausea was higher at the beginning of SYMLIN treatment and decreased with time in most patients. The incidence and severity of nausea are reduced when SYMLIN is gradually increased to the recommended doses.

About Diabetes

Diabetes is a complex metabolic disease characterized by high blood glucose levels resulting from a deficiency of both insulin and amylin secretion. Diabetes represents a large and growing market in the United States, affecting more than 20 million Americans and growing at three times the rate of population growth. Approximately 4.2 million patients with diabetes use insulin. Diabetes is the sixth leading cause of death in the United States. Poor control of blood glucose may result in severe long-term complications such as cardiovascular disease, blindness, kidney failure, nerve damage and amputation.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including risks that SYMLIN and SymlinPen may be affected by unexpected new data, technical issues, or manufacturing and supply issues; risks that the results of clinical trials may not be predictive of future results; and risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for SYMLIN and SymlinPen. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.

Alert: Photo advisory coming soon to accompany this release.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
2. Advertisements for Medical Devices, Implants Should Carry Warnings of Dangerous Side Effects, Infections
3. Radiology Support Devices Introduces New Breathing Phantom System
4. SPO Medical Unveils New Oximetry Devices for European Markets
5. Hazardous Advanced Micro Devices (A.M.D.) Clean Room Chemicals Caused Multiple Birth Defects, Lawsuit Alleges
6. DeviceSpace Career Fair Opens Doors for Hundreds of Medical Device and Diagnostics Career Candidates
7. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cardio Devices, and the HealthShares(TM) Orthopedic Repair Indexes
8. Do women fare worse with some heart devices?
9. Brain measurements could lead to better devices to move injured or artificial limbs
10. Nationwide independent Taser study results suggest devices are safe
11. HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology: